Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK/PD study of avelumab in previously treated classical Hodgkin lymphoma
NL-OMON43446Phase 1Withdrawn
- Sponsor
- Pfizer
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of avelumab in classical Hodgkin lymphoma (cHL) (6 arms), sponsored by Pfizer. Primary endpoints: Percent target occupancy in peripheral blood immune cells and Avelumab pharmacokinetic parameters. Planned start Mar 2016; status: withdrawn.
02
Drugs
avelumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NL-OMON43446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43446.